Rayner appoints VP Corporate Development to lead global commercial expansion

Posted on 24/11/2021

NOVEMBER 24, 2021 – Worthing, United Kingdom. Rayner, a leading ophthalmology company focused on optimising visual outcomes for patients and surgeons, today announced the appointment of Dr Rob Nadler to the role of VP Corporate Development. Dr Nadler will play a critical role on the executive team, overseeing the company’s M&A strategy and brings invaluable clinical, strategic and financial experience to this task.

“The addition of Rob strengthens our leadership team as Rayner is on the cusp of a key inflection point under new ownership. We continue our expansion into the US and China with recent approvals of RayOne EMV and RayOne Aspheric respectively, our continued ‘go-direct’ strategy and year-on-year growth in our broader premium and monofocal IOL portfolios,” said Tim Clover, Chief Executive Officer of Rayner. “Rob brings an extensive track record in the industry, having been involved as a banker in many of the recent transactions in the space, and together with his background as an ophthalmic surgeon, brings a unique view to our future growth strategy.”

Dr Nadler added: “Having known the company and management team for several years, and seen and used their products in surgery, I have been impressed with Rayner’s long history in the sector and the disruptive technology that continues to differentiate it from its peers. I am excited about the opportunity to help continue building the company.”

Dr Nadler spent over a decade advising healthcare companies on strategic and financial matters. He was previously at William Blair where he was the Head of Medtech in Europe. Prior to William Blair, Dr Nadler was a member of the Global Healthcare M&A teams at Perella Weinberg Partners, Nomura and commenced his banking career at Lehman Brothers. He holds a medical and science degree from Imperial College and trained as an ophthalmic surgeon practicing in the UK.



About Rayner

Since the implantation of the first Rayner intraocular lens by Sir Harold Ridley 1949, Rayner has continuously pioneered intraocular lens (IOL) design with a goal to improve vision and restore sight worldwide. Today, Rayner’s mission remains to deliver innovative and clinically superior ophthalmic products that respond to the expectations of our global customers to improve the sight and quality of life of their patients.

Headquartered in Worthing, United Kingdom, Rayner markets its IOL, OVD, dry eye and digital health portfolio worldwide in over 80 countries through a network of distributors, with direct sales teams in the United Kingdom, USA, Germany, Austria, Switzerland, Italy, India, Spain and Portugal.

For further information and media enquiries, please contact Rayner: marketingteam@rayner.com

EC 2021-89 11/21

Share this article